Fig. 3
From: Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions
Change from baseline in SGRQ total score at Week 24 by comorbidity category. Change from baseline in SGRQ total score was analyzed using analysis of covariance. The currently accepted minimum clinically important difference for SGRQ is 4 units (established in an average population of patients with chronic obstructive pulmonary disease) [25]. p-interaction < 0.1. AR allergic rhinitis/hay fever; CI confidence interval; GERD gastroesophageal reflux disease; mepo mepolizumab; SGRQ St George’s Respiratory Questionnaire